TRexBio Inc


TRexBio Inc.

In December 2021, Johnson & Johnson Innovation facilitated a multiyear research collaboration and licensing agreement between Janssen Pharmaceuticals NV and TRexBio Inc., a discovery stage company decoding tissue immune biology to create revolutionary therapeutics.

The collaboration is focused on discovery of novel-tissues targeted therapeutics using TRexBio's proprietary Deep Biology platform which combines high resolutio sequencing of human tissues, cutting-edge computational biology tools, and scalable transactional biology assay systems into an optimized workflow, enabling efficient discovery and functional characteristics of unique tissue specific targets.

Our differentiated Deep Biology platform has the potential to uncover truly unique insights, and we look forward to leveraging this collaboration as part of our mission to bring new medicines to patients.

Johnston Erwin
CEO, TRexBio